The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Barbara Engelhardt moves her computational and statistics lab to Gladstone
_256_384.jpg)
In the period April to August 2021, exports stood at Rs 73,469.29 crores compared to Rs 72,275.22 crores for the period April to August 2020 a growth of 1.65 per cent
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
_256_384.jpg)
ICMR receives conditional exemption from Drone Rules 2021 to speed up vaccine delivery in the A&N Islands, Manipur and Nagaland
The platform revolutionizes how providers deliver financial services by radically simplifying the patient financial experience
The tracker gives week by week coverage of the first and second dose of vaccine and also their effectiveness
Subscribe To Our Newsletter & Stay Updated
